首页 > 最新文献

International Journal of Endocrine Oncology最新文献

英文 中文
Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion: a retrospective study 神经内分泌肿瘤伴综合征性血管活性肠多肽高分泌:回顾性研究
IF 1.2 Pub Date : 2017-03-23 DOI: 10.2217/IJE-2016-0012
P. Antonodimitrakis, H. Olofsson, L. Grimelius, A. Sundin, C. Wassberg, D. Granberg, B. Skogseid, B. Eriksson
Aim: Vasoactive intestinal polypeptide producing neuroendocrine tumors are rare and cause severe hormonal symptoms. Patients/methods: Eighteen patients with vasoactive intestinal polypeptide producing neuroendocrine tumors were analyzed with reviews of medical records, radiology and tumor tissue specimens. Results: Twelve patients (67%) had liver metastases at diagnosis. Chemotherapy, somatostatin analogs and interferon were given as medical therapies. Streptozocin/5-fluorouracil produced an objective response in 40% of the evaluable patients. Somatostatin analogs gave a clinical/biochemical response in eight out of nine patients. Transarterial embolization of the liver and peptide receptor radionuclide therapy was given to refractory cases. Sixteen patients died during the observation period. The median overall survival from diagnosis was 102 months. Conclusion: Systemic chemotherapy and somatostatin analogs should be given in cases of advanced disease or for hormonal symptoms.
目的:产生血管活性肠多肽的神经内分泌肿瘤是一种罕见的引起严重激素症状的肿瘤。患者/方法:回顾性分析18例血管活性肠多肽产生神经内分泌肿瘤患者的病历资料、影像学资料和肿瘤组织标本。结果:12例(67%)患者在诊断时有肝转移。化疗、生长抑素类似物和干扰素作为药物治疗。链脲菌素/5-氟尿嘧啶在40%的可评估患者中产生客观反应。生长抑素类似物对9名患者中的8名产生了临床/生化反应。对难治性病例给予肝动脉栓塞和肽受体放射性核素治疗。16例患者在观察期内死亡。诊断后的中位总生存期为102个月。结论:对于晚期疾病或出现激素症状的患者应给予全身化疗和生长抑素类似物。
{"title":"Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion: a retrospective study","authors":"P. Antonodimitrakis, H. Olofsson, L. Grimelius, A. Sundin, C. Wassberg, D. Granberg, B. Skogseid, B. Eriksson","doi":"10.2217/IJE-2016-0012","DOIUrl":"https://doi.org/10.2217/IJE-2016-0012","url":null,"abstract":"Aim: Vasoactive intestinal polypeptide producing neuroendocrine tumors are rare and cause severe hormonal symptoms. Patients/methods: Eighteen patients with vasoactive intestinal polypeptide producing neuroendocrine tumors were analyzed with reviews of medical records, radiology and tumor tissue specimens. Results: Twelve patients (67%) had liver metastases at diagnosis. Chemotherapy, somatostatin analogs and interferon were given as medical therapies. Streptozocin/5-fluorouracil produced an objective response in 40% of the evaluable patients. Somatostatin analogs gave a clinical/biochemical response in eight out of nine patients. Transarterial embolization of the liver and peptide receptor radionuclide therapy was given to refractory cases. Sixteen patients died during the observation period. The median overall survival from diagnosis was 102 months. Conclusion: Systemic chemotherapy and somatostatin analogs should be given in cases of advanced disease or for hormonal symptoms.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2017-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2016-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46522612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on microRNA as biomarkers of adrenocortical cancer: perspective on circulating microRNA microRNA作为肾上腺皮质癌生物标志物的最新进展:循环microRNA的观点
IF 1.2 Pub Date : 2017-03-23 DOI: 10.2217/IJE-2017-0001
P. Igaz
{"title":"Update on microRNA as biomarkers of adrenocortical cancer: perspective on circulating microRNA","authors":"P. Igaz","doi":"10.2217/IJE-2017-0001","DOIUrl":"https://doi.org/10.2217/IJE-2017-0001","url":null,"abstract":"","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2017-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2017-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48479946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastro-entero-pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: a therapy update 1型多发性内分泌瘤中的胃-肠-胰神经内分泌肿瘤:治疗进展
IF 1.2 Pub Date : 2017-03-23 DOI: 10.2217/IJE-2016-0017
F. Tonelli, F. Marini, F. Giusti, M. Brandi
Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are the second most common tumors in multiple endocrine neoplasia type 1 (MEN1), mainly occurring in pancreatic islets and duodenum, usually as multiple tumors. They can manifest as both nonfunctioning and functioning tumors. Currently, surgical removal of GEP-NETs in MEN1 represents the gold standard curative approach. Conventional medical therapies for sporadic GEP-NETs showed to be effective also in a percentage of MEN1 patients. Innovative medical therapies, that have demonstrated to be effective on sporadic GEP-NETs, still need to be evaluated on MEN1 patients in prospective clinical trials and long-term follow-up. This review resumes current knowledge of MEN1 GEP-NETs, discussing surgical and medical approaches, genetic and molecular bases of tumorigenesis, and presenting novel possible drug therapies.
胃-肠-胰腺神经内分泌肿瘤(GEP-NETs)是多发性内分泌瘤1型(MEN1)中第二常见的肿瘤,主要发生在胰岛和十二指肠,通常为多发肿瘤。它们可以表现为无功能和功能性肿瘤。目前,手术切除MEN1患者的GEP-NETs是金标准治疗方法。对散发的GEP-NETs的常规药物治疗在一定比例的MEN1患者中也显示有效。已证明对散发性GEP-NETs有效的创新医学疗法,仍需在前瞻性临床试验和长期随访中对MEN1患者进行评估。本文回顾了MEN1 GEP-NETs的现有知识,讨论了手术和医学方法,肿瘤发生的遗传和分子基础,并提出了新的可能的药物治疗方法。
{"title":"Gastro-entero-pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: a therapy update","authors":"F. Tonelli, F. Marini, F. Giusti, M. Brandi","doi":"10.2217/IJE-2016-0017","DOIUrl":"https://doi.org/10.2217/IJE-2016-0017","url":null,"abstract":"Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are the second most common tumors in multiple endocrine neoplasia type 1 (MEN1), mainly occurring in pancreatic islets and duodenum, usually as multiple tumors. They can manifest as both nonfunctioning and functioning tumors. Currently, surgical removal of GEP-NETs in MEN1 represents the gold standard curative approach. Conventional medical therapies for sporadic GEP-NETs showed to be effective also in a percentage of MEN1 patients. Innovative medical therapies, that have demonstrated to be effective on sporadic GEP-NETs, still need to be evaluated on MEN1 patients in prospective clinical trials and long-term follow-up. This review resumes current knowledge of MEN1 GEP-NETs, discussing surgical and medical approaches, genetic and molecular bases of tumorigenesis, and presenting novel possible drug therapies.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2017-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2016-0017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41787406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. PPIs时代佐林格-埃利森综合征的诊断,错误的胃泌素检测,敏感的成像和有限的酸分泌测试。
IF 1.2 Pub Date : 2017-01-01 Epub Date: 2017-10-11 DOI: 10.2217/ije-2017-0018
David C Metz, Guillaume Cadiot, Pierre Poitras, Tetsuhide Ito, Robert T Jensen

In recent years the diagnosis of Zollinger-Ellison syndrome (ZES) has become increasingly controversial with several new approaches and criteria proposed, differing from the classical biochemical criterion of inappropriate hypergastrinemia (i.e., hypergastrinemia in the presence of hyperchlorhydria) (Table 1). These changes have come about because of the difficulty and potential dangers of stopping proton pump inhibitors (PPIs) for gastric acid analysis; the recognition than many of the current assays used to assess gastrin concentrations are unreliable; the development of sensitive imaging modalities that detect neuroendocrine tumors (NETs) including an increasing number of the primary gastrinomas; the increased use of percutaneous or endoscopic ultrasound (EUS)-directed biopsies/cytology and the general lack of availability of acid secretory testing. In this article we will discuss the basis for these controversies, review the proposed changes in diagnostic approaches and make recommendations for supporting the diagnosis of ZES in the modern era.

近年来,佐林格-埃里森综合征(Zollinger-Ellison syndrome, ZES)的诊断越来越有争议,提出了几种新的方法和标准,不同于不适当高胃泌素血症的经典生化标准(即高氯酸血症存在的高胃泌素血症)(表1)。这些变化的发生是因为停止质子泵抑制剂(PPIs)进行胃酸分析的困难和潜在危险;认识到许多目前用于评估胃泌素浓度的测定方法是不可靠的;检测神经内分泌肿瘤(NETs)的敏感成像模式的发展,包括越来越多的原发性胃泌素瘤;经皮或内镜超声(EUS)指导下的活检/细胞学检查的使用增加,以及酸分泌检测的普遍缺乏。在本文中,我们将讨论这些争议的基础,回顾诊断方法的拟议变化,并为支持现代ZES的诊断提出建议。
{"title":"Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.","authors":"David C Metz,&nbsp;Guillaume Cadiot,&nbsp;Pierre Poitras,&nbsp;Tetsuhide Ito,&nbsp;Robert T Jensen","doi":"10.2217/ije-2017-0018","DOIUrl":"https://doi.org/10.2217/ije-2017-0018","url":null,"abstract":"<p><p>In recent years the diagnosis of Zollinger-Ellison syndrome (ZES) has become increasingly controversial with several new approaches and criteria proposed, differing from the classical biochemical criterion of inappropriate hypergastrinemia (i.e., hypergastrinemia in the presence of hyperchlorhydria) (Table 1). These changes have come about because of the difficulty and potential dangers of stopping proton pump inhibitors (PPIs) for gastric acid analysis; the recognition than many of the current assays used to assess gastrin concentrations are unreliable; the development of sensitive imaging modalities that detect neuroendocrine tumors (NETs) including an increasing number of the primary gastrinomas; the increased use of percutaneous or endoscopic ultrasound (EUS)-directed biopsies/cytology and the general lack of availability of acid secretory testing. In this article we will discuss the basis for these controversies, review the proposed changes in diagnostic approaches and make recommendations for supporting the diagnosis of ZES in the modern era.</p>","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ije-2017-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35731178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 47
Advances in diagnosis and management of familial pituitary adenomas 家族性垂体腺瘤的诊断与治疗进展
IF 1.2 Pub Date : 2016-11-04 DOI: 10.2217/IJE-2016-0009
H. Jedidi, L. Rostomyan, I. Potorac, F. Depierreux, P. Petrossians, A. Beckers
Familial pituitary adenomas account for approximately 5–8% of all pituitary adenomas. Besides the adenomas occurring as part of syndromic entities that group several endocrine or nonendocrine disorders (multiple endocrine neoplasia type 1 or 4, Carney complex and McCune–Albright syndrome), 2–3% of familial pituitary adenomas fit into the familial isolated pituitary adenomas (FIPA) syndrome, an autosomal dominant condition with incomplete penetrance. About 20% of FIPA cases are due to mutations in the AIP gene and have distinct clinical characteristics. Recent findings have isolated a new non-AIP FIPA syndrome called X-linked acrogigantism, resulting from a microduplication that always includes the GPR101 gene. These new advances in the field of pituitary disease are opening up a new challenging domain to both clinicians and researchers. This review will focus on these recent findings and their contribution to the diagnosis and the management of familial pituitary adenomas.
家族性垂体腺瘤约占所有垂体腺瘤的5-8%。除了腺瘤是将几种内分泌或非内分泌疾病(1型或4型多发性内分泌瘤、卡尼综合征和麦克恩-奥尔布赖特综合征)归为综合征的一部分外,2-3%的家族性垂体腺瘤属于家族性孤立性垂体腺瘤(FIPA)综合征,这是一种不完全外显的常染色体显性遗传病。约20%的FIPA病例是由AIP基因突变引起的,具有明显的临床特征。最近的研究发现分离出了一种新的非aip FIPA综合征,称为x连锁肢巨人症,由总是包含GPR101基因的微复制引起。垂体疾病领域的这些新进展为临床医生和研究人员开辟了一个新的具有挑战性的领域。本文将重点介绍这些最新发现及其对家族性垂体腺瘤的诊断和治疗的贡献。
{"title":"Advances in diagnosis and management of familial pituitary adenomas","authors":"H. Jedidi, L. Rostomyan, I. Potorac, F. Depierreux, P. Petrossians, A. Beckers","doi":"10.2217/IJE-2016-0009","DOIUrl":"https://doi.org/10.2217/IJE-2016-0009","url":null,"abstract":"Familial pituitary adenomas account for approximately 5–8% of all pituitary adenomas. Besides the adenomas occurring as part of syndromic entities that group several endocrine or nonendocrine disorders (multiple endocrine neoplasia type 1 or 4, Carney complex and McCune–Albright syndrome), 2–3% of familial pituitary adenomas fit into the familial isolated pituitary adenomas (FIPA) syndrome, an autosomal dominant condition with incomplete penetrance. About 20% of FIPA cases are due to mutations in the AIP gene and have distinct clinical characteristics. Recent findings have isolated a new non-AIP FIPA syndrome called X-linked acrogigantism, resulting from a microduplication that always includes the GPR101 gene. These new advances in the field of pituitary disease are opening up a new challenging domain to both clinicians and researchers. This review will focus on these recent findings and their contribution to the diagnosis and the management of familial pituitary adenomas.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2016-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2016-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68216767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Signaling pathways in medullary thyroid carcinoma: therapeutic implications 甲状腺髓样癌的信号通路:治疗意义
IF 1.2 Pub Date : 2016-11-03 DOI: 10.2217/IJE-2016-0014
Zahra Nozhat, M. Hedayati, Hoda Pourhassan
Medullary thyroid cancer (MTC) is the third most frequent thyroid cancer arising from thyroid parafollicular cells. Surgery is the first-line strategy in treatment of MTC but disease relapse and patient's death have been observed in approximately two out of three of MTC cases. Identification of molecular mechanisms and different signaling pathways has offered new insights for disease treatment. The development of tyrosine kinase inhibitors targeting these pathways has provided a promising landscape for prevention of progression in patients with advanced metastatic MTC. In this review article different altered molecular pathways implicated in the development of MTC and the therapeutic strategies based on targeting the identified signaling pathways have been summarized.
甲状腺髓样癌(MTC)是第三种最常见的甲状腺癌,起源于甲状腺滤泡旁细胞。手术是治疗MTC的一线策略,但在大约三分之二的MTC病例中观察到疾病复发和患者死亡。分子机制和不同信号通路的识别为疾病治疗提供了新的见解。针对这些途径的酪氨酸激酶抑制剂的开发为预防晚期转移性MTC患者的进展提供了一个有希望的前景。本文综述了与MTC发展相关的不同分子通路的改变以及基于已识别的信号通路的治疗策略。
{"title":"Signaling pathways in medullary thyroid carcinoma: therapeutic implications","authors":"Zahra Nozhat, M. Hedayati, Hoda Pourhassan","doi":"10.2217/IJE-2016-0014","DOIUrl":"https://doi.org/10.2217/IJE-2016-0014","url":null,"abstract":"Medullary thyroid cancer (MTC) is the third most frequent thyroid cancer arising from thyroid parafollicular cells. Surgery is the first-line strategy in treatment of MTC but disease relapse and patient's death have been observed in approximately two out of three of MTC cases. Identification of molecular mechanisms and different signaling pathways has offered new insights for disease treatment. The development of tyrosine kinase inhibitors targeting these pathways has provided a promising landscape for prevention of progression in patients with advanced metastatic MTC. In this review article different altered molecular pathways implicated in the development of MTC and the therapeutic strategies based on targeting the identified signaling pathways have been summarized.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2016-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2016-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68217335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma lenvatinib对进展性、难治性、转移性副神经节瘤的持久疗效
IF 1.2 Pub Date : 2016-11-03 DOI: 10.2217/IJE-2016-0015
S. Jasim, A. Chintakuntlawar, K. Bible
Paragangliomas are rare, often vascular, endocrine tumors that are sometimes malignant. Antiangiogenic agents may play a role in treating advanced disease. We report a case of a 49-year-old woman with metastatic and rapidly progressive secretory paraganglioma (with germ line SDHB p.V140F–c.418G>T mutation) who responded rapidly and durably to the VEGFR- and multi-targeted kinase inhibitor, lenvatinib, despite progression through prior cytotoxic and kinase inhibitor therapy. She incurred dramatic response within 48 h of lenvatinib initiation, but developed parallel transient mild tumor lysis syndrome and, later, localized radiation ‘recall’ pneumonitis. Follow-up assessments demonstrated a confirmed response evaluation criteria in solid tumors response as well as symptomatic and biochemical improvement. Lenvatinib may represent a promising therapeutic for further development in treating metastatic paraganglioma.
副神经节瘤是罕见的,通常是血管、内分泌肿瘤,有时是恶性的。抗血管生成药物可能在晚期疾病的治疗中发挥作用。我们报告一例49岁女性转移性和快速进展的分泌性副神经节瘤(生殖系SDHB p.V140F-c)。418G>T突变)患者对VEGFR-和多靶点激酶抑制剂lenvatinib有快速和持久的反应,尽管通过先前的细胞毒性和激酶抑制剂治疗进展。她在lenvatinib启动后48小时内出现了显著的反应,但出现了平行的短暂性轻度肿瘤溶解综合征,后来出现了局限性放射“回忆性”肺炎。随访评估证实了实体瘤反应以及症状和生化改善的反应评价标准。Lenvatinib可能代表了一种有希望的治疗转移性副神经节瘤的进一步发展。
{"title":"Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma","authors":"S. Jasim, A. Chintakuntlawar, K. Bible","doi":"10.2217/IJE-2016-0015","DOIUrl":"https://doi.org/10.2217/IJE-2016-0015","url":null,"abstract":"Paragangliomas are rare, often vascular, endocrine tumors that are sometimes malignant. Antiangiogenic agents may play a role in treating advanced disease. We report a case of a 49-year-old woman with metastatic and rapidly progressive secretory paraganglioma (with germ line SDHB p.V140F–c.418G>T mutation) who responded rapidly and durably to the VEGFR- and multi-targeted kinase inhibitor, lenvatinib, despite progression through prior cytotoxic and kinase inhibitor therapy. She incurred dramatic response within 48 h of lenvatinib initiation, but developed parallel transient mild tumor lysis syndrome and, later, localized radiation ‘recall’ pneumonitis. Follow-up assessments demonstrated a confirmed response evaluation criteria in solid tumors response as well as symptomatic and biochemical improvement. Lenvatinib may represent a promising therapeutic for further development in treating metastatic paraganglioma.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2016-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2016-0015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68217344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Resection of primary gastroenteropancreatic neuroendocrine tumors in the presence of irresectable liver metastases 原发性胃肠胰神经内分泌肿瘤伴不可切除的肝转移的切除
IF 1.2 Pub Date : 2016-11-03 DOI: 10.2217/IJE-2016-0010
Philippa K Wadsworth, Robert P. Jones, G. Poston
Gastroenteropancreatic neuroendocrine tumors often present at an advanced stage and carry a variable prognosis, with many patients living long periods even with metastatic disease. Resection of the primary tumor when liver metastases are unresectable is a contentious subject with no consensus between existing guidelines. A number of recent studies have suggested a potential survival benefit as well as improved symptom control with resection. With variable results from nonoperative management strategies, the risk:benefit ratio of resection of the primary tumor may be favorable for carefully selected patients.
胃肠胰神经内分泌肿瘤通常出现在晚期,预后不一,许多患者即使有转移性疾病也能存活很长时间。当肝转移无法切除时,切除原发肿瘤是一个有争议的话题,现有指南之间没有共识。最近的一些研究表明,切除有潜在的生存益处以及改善的症状控制。由于非手术治疗策略的不同结果,对于精心挑选的患者,切除原发肿瘤的风险:收益比可能是有利的。
{"title":"Resection of primary gastroenteropancreatic neuroendocrine tumors in the presence of irresectable liver metastases","authors":"Philippa K Wadsworth, Robert P. Jones, G. Poston","doi":"10.2217/IJE-2016-0010","DOIUrl":"https://doi.org/10.2217/IJE-2016-0010","url":null,"abstract":"Gastroenteropancreatic neuroendocrine tumors often present at an advanced stage and carry a variable prognosis, with many patients living long periods even with metastatic disease. Resection of the primary tumor when liver metastases are unresectable is a contentious subject with no consensus between existing guidelines. A number of recent studies have suggested a potential survival benefit as well as improved symptom control with resection. With variable results from nonoperative management strategies, the risk:benefit ratio of resection of the primary tumor may be favorable for carefully selected patients.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2016-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2016-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68216777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of pheochromocytomas and paragangliomas: genetic approach? 嗜铬细胞瘤和副神经节瘤的治疗:遗传学方法?
IF 1.2 Pub Date : 2016-11-03 DOI: 10.2217/IJE-2016-0016
A. Violante, T. Ortiga-Carvalho, M. H. Costa, M. Vaisman
Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are neuroendocrine tumors derived from the chromaffin tissue of the adrenal medulla or from extra-adrenal sympathetic and parasympathetic paraganglia. These tumors affect one in 2500–6500 people, with 500–1600 patients diagnosed annually in the USA. Its real incidence is likely to be much higher, and many patients may die undiagnosed. It is a rare cause of secondary hypertension, with an incidence of 0.1–0.6%. PHEOs are more common than PGLs, and 5–7% is related to hormonal secretion. The average age of diagnosis is 43 years, but 10–20% of PHEO/PGL patients are children, and the tumors are generally associated with genetic conditions. The worldwide consensus is that people with PHEOs/PGLs should undergo a mandatory genetic investigation, especially with multiple injuries and those who are younger. Although many PHEOs are sporadic and benign, approximately 30% of familial tumor cases have been identified. Multiple endocrine neoplasia type 2, von Hippel–Li...
嗜铬细胞瘤(PHEOs)和副神经节瘤(PGLs)是来源于肾上腺髓质的染色质组织或肾上腺外交感和副交感神经节的神经内分泌肿瘤。每2500-6500人中就有1人患有这些肿瘤,在美国每年诊断出500-1600例患者。它的真实发病率可能要高得多,许多患者可能在未被诊断的情况下死亡。它是继发性高血压的罕见病因,发病率为0.1-0.6%。pheo比pgl更常见,其中5-7%与激素分泌有关。平均诊断年龄为43岁,但10-20%的PHEO/PGL患者为儿童,肿瘤通常与遗传条件有关。世界范围内的共识是pheo / pgl患者应该接受强制性的基因调查,特别是多发损伤和年轻患者。虽然许多pheo是散发性和良性的,但大约30%的家族性肿瘤病例已被确定。多发性内分泌肿瘤2型,von Hippel-Li…
{"title":"Treatment of pheochromocytomas and paragangliomas: genetic approach?","authors":"A. Violante, T. Ortiga-Carvalho, M. H. Costa, M. Vaisman","doi":"10.2217/IJE-2016-0016","DOIUrl":"https://doi.org/10.2217/IJE-2016-0016","url":null,"abstract":"Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are neuroendocrine tumors derived from the chromaffin tissue of the adrenal medulla or from extra-adrenal sympathetic and parasympathetic paraganglia. These tumors affect one in 2500–6500 people, with 500–1600 patients diagnosed annually in the USA. Its real incidence is likely to be much higher, and many patients may die undiagnosed. It is a rare cause of secondary hypertension, with an incidence of 0.1–0.6%. PHEOs are more common than PGLs, and 5–7% is related to hormonal secretion. The average age of diagnosis is 43 years, but 10–20% of PHEO/PGL patients are children, and the tumors are generally associated with genetic conditions. The worldwide consensus is that people with PHEOs/PGLs should undergo a mandatory genetic investigation, especially with multiple injuries and those who are younger. Although many PHEOs are sporadic and benign, approximately 30% of familial tumor cases have been identified. Multiple endocrine neoplasia type 2, von Hippel–Li...","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2016-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2016-0016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68217355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Akt as a potential prognostic marker in neuroendocrine tumors: a possibility? Akt作为神经内分泌肿瘤的潜在预后标志物:一种可能性?
IF 1.2 Pub Date : 2016-11-01 DOI: 10.2217/IJE-2016-0019
A. Hague, Helen L Robbins
{"title":"Akt as a potential prognostic marker in neuroendocrine tumors: a possibility?","authors":"A. Hague, Helen L Robbins","doi":"10.2217/IJE-2016-0019","DOIUrl":"https://doi.org/10.2217/IJE-2016-0019","url":null,"abstract":"","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2016-0019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68217391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Endocrine Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1